Immunosuppressive therapy of myocarditis and inflammatory cardiomyopathy in the light of new data
- PMID: 36263783
- DOI: 10.1093/eurheartj/ehac500
Immunosuppressive therapy of myocarditis and inflammatory cardiomyopathy in the light of new data
Conflict of interest statement
Conflict of interest: The authors designed, coordinate and participate in the Scientific Excellence Committee of the IMPROVE-MC trial.
Comment in
-
Individualized immunosuppression in virus-negative inflammatory cardiomyopathy.Eur Heart J. 2022 Dec 1;43(45):4760. doi: 10.1093/eurheartj/ehac559. Eur Heart J. 2022. PMID: 36263787 No abstract available.
Comment on
-
Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial.Eur Heart J. 2022 Sep 21;43(36):3463-3473. doi: 10.1093/eurheartj/ehac348. Eur Heart J. 2022. PMID: 35831932 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources